peterschreiber.media
- BofA began protection of Biohaven (NYSE:BHVN) with a purchase ranking, citing its drug improvement applications for temper and autoimmune issues.
- The funding financial institution mentioned it favored Biohaven’s “’fast-follower’ approach of advancing drugs that rivals have been developing – allowing it to capitalize on an already de-risked clinical path.”
- BofA added that whereas it noticed Biohaven’s (BHVN) efforts as “expansive,” it believed administration had a “track record of prudent capital allocation.”
- The financial institution set its worth goal for the inventory at $52.
Source: Seekingalpha